Ahead of CPHI Milan, EPM spoke to Thierry Van Nieuwenhove, CEO of Quotient Sciences, to explore how the company is innovating to meet the growing demand for personalised medicine through AI, partnerships and meeting sustainability goals.
Q. How are you innovating to meet the growing demand for personalised medicine and cell and gene therapies?
Quotient Sciences supports the development of more personalised treatments for paediatric patients and clinical trial materials manufacturing. We have a lot of expertise in developing paediatric formulations that better meet the needs of children and adolescents, as well as their caregivers. For example, selecting age-appropriate dosage form(s) and appropriate excipients to use in the formulations are two major considerations in developing paediatric therapies and where we have lent our expertise to customers.